This expansion was greater than that seen with an anti-OX40 agonist antibody. When the two antibodies were given together, they stimulated greater expansion of CD8+ T cells than either alone ...

and effective antibody-fusion protein. The approach was used to develop ATOR-1015 and ATOR-1144, the former targets CTLA-4 and OX40 while the latter targets CTLA-4 and glucocorticoid-induced tumor ...

In January, Sanofi agreed a $1.45 billion deal to acquire UK biotech Kymab and its lead drug KY1005, an OX40 antibody that like KHK4083 has already cleared a phase 2 trial in atopic dermatitis.

APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase ...

Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website ...